Monday, November 3, 2025 11/3/2025

Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B)

Award Number: R01DA045724
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/15/2019
PERIOD OF PERFORMANCE END DATE: 01/31/2026

Group Awards By:

View Award Description

Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) - Abstract Untreated opioid use disorder (OUD) is a continuing public health emergency in the United States. OUD is associated with significant morbidity and mortality, including overdose death. Buprenorphine is an effective treatment for OUD, but most individuals who need such treatment do not access it. Public STD clinics are high-volume, episodic care medical settings that serve a high-risk population, often on a walk-in basis. STD clinic patients have high prevalence of OUD and health-risking behaviors. This proposed study, entitled Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B), will examine OUD treatment linkage strategies for opioid-dependent patients seeking services at public STD clinics. This three-arm, parallel randomized clinical trial (RCT) will compare Usual Care (UC), vs. referral via Patient Navigation (PN), vs. Patient Navigation with STD-clinic initiated buprenorphine (PN+BUP). The UC Arm will include standard services at the STD clinic. The PN Arm will include all UC Arm services, with the addition of a Patient Navigator who will assist the participant in selecting a community OUD treatment program, facilitate an intake appointment, help to resolve barriers and coordinate OUD treatment entry, and support early retention in OUD treatment. The PN+BUP Arm will include all PN Arm services, with the addition of meeting with the STD clinic’s buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to OUD treatment in the community. Research assessments consisting of a structured interview battery and biomarkers for drug use and STDs will be conducted at baseline, 3-, and 6-month follow-up. Selected outcomes will be examined through 12-months via health record linkage methods. The study will examine participant outcomes in the domains of: (1) OUD treatment entry and retention, (2) Opioid use and related problems (including fatal and non-fatal overdose), and (3) HIV/STD-related outcomes. This innovative study could identify new approaches to engaging a high-risk patient population in OUD treatment. The study could have high impact because findings could be scaled to STD clinics throughout the nation, spurring novel integration across two traditionally separate service sectors of STD care and OUD treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	5	1/29/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $559,848 )
2024	2024	FRIENDS RESEARCH INSTITUTE, INC.	1040 PARK AVE	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	5	4/25/2024	NON-COMPETING CONTINUATION	$55,985
2024	2024	FRIENDS RESEARCH INSTITUTE, INC.	1040 PARK AVE	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	5	1/8/2024	NON-COMPETING CONTINUATION	$503,863
														Subtotal = $559,848

Issue Date FY: 2023 ( Subtotal = $688,020 )
2023	2023	FRIENDS RESEARCH INSTITUTE INC	1040 PARK AVE	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	4	1/30/2023	NON-COMPETING CONTINUATION	$688,020
														Subtotal = $688,020

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	3	1/20/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $691,445 )
2021	2021	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	3	2/9/2021	NON-COMPETING CONTINUATION	$691,445
														Subtotal = $691,445

Issue Date FY: 2020 ( Subtotal = $694,522 )
2020	2020	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	001	2	1/17/2020	NON-COMPETING CONTINUATION	$0
2020	2020	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	2	1/16/2020	NON-COMPETING CONTINUATION	$694,522
														Subtotal = $694,522

Issue Date FY: 2019 ( Subtotal = $707,730 )
2019	2019	FRIENDS RESEARCH INSTITUTE, INC	1040 PARK AVE STE 103	BALTIMORE	MD	21201	BALTIMORE CITY	USA	Drug Use and Addiction Research Programs	000	1	4/2/2019	NEW	$707,730
														Subtotal = $707,730

Grand Total All Awards = $3,341,565

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B)

Award Number: R01DA045724

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/15/2019

PERIOD OF PERFORMANCE END DATE: 01/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer